Pharmacy Benefits Manager Accountability Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Pharmacy Benefits Manager Accountability Act (H.R. 2679) is a legislative proposal introduced in the 118th Congress aimed at increasing accountability for pharmacy benefits managers (PBMs). PBMs are intermediaries that manage prescription drug benefits on behalf of health insurers and employers. Although the bill text and detailed summary are not available, the title and policy area indicate the bill focuses on regulatory or oversight measures to address the role and practices of PBMs in the healthcare system. The bill was referred to the House Subcommittee on Health but ultimately failed or expired without further action.
H.R. 2679 sought to enhance oversight of pharmacy benefits managers but did not advance beyond subcommittee referral and expired in the 118th Congress.
- The bill targets pharmacy benefits managers, entities that influence prescription drug pricing and access.
- It was introduced in the House of Representatives during the 118th Congress and referred to the Subcommittee on Health.
- No official summary or full text is publicly available, limiting detailed analysis of specific provisions.
['Patients and consumers who use prescription drug benefits', 'Health insurers and employers seeking transparency in drug benefit management', 'Regulatory bodies overseeing healthcare and pharmaceutical markets']
['Lack of publicly available full text and summary limits understanding of implementation requirements and enforcement mechanisms', 'Potential administrative costs or regulatory burdens on PBMs and related entities', 'Unclear scope of authority and oversight provisions due to missing bill details']
The bill was introduced in the 118th Congress and referred to the House Subcommittee on Health. It did not progress further and was classified as failed or expired as of December 2025. The absence of detailed legislative history or debate records restricts insight into the bill's support or opposition dynamics.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential increased regulatory scrutiny on PBMs could influence drug pricing negotiations and benefit design.', 'Greater transparency or accountability requirements might affect administrative costs for insurers and employers.', 'Changes in PBM operations could impact pharmacies, pharmaceutical manufacturers, and patients indirectly.']
The absence of an official summary and full bill text significantly limits the ability to analyze the bill's specific provisions, enforcement mechanisms, and fiscal impacts. Transparency about legislative content is essential for informed public and stakeholder engagement. The bill's failure to advance past subcommittee referral also restricts insight into congressional deliberations or amendments.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.